The global toxicogenomics market was valued at USD 1.62 billion in 2025. The market is estimated at USD 1.78 billion in 2026 and is projected to reach USD 4.68 billion by 2036, at a CAGR of 10.1% during the forecast period 2026-2036. This report assesses the regulatory move toward new approach methodologies (NAMs), drug safety attrition, profiling technologies, databases, the value chain, cost per sample, the supplier landscape, and growth opportunities.
The market includes the products and services used to measure how drugs, chemicals, and environmental agents alter gene expression and related molecular processes, so that hazards can be found, toxic mechanisms explained, and safety decisions supported. Covered methods include whole-transcriptome RNA sequencing, targeted and high-throughput transcriptomics, microarrays, qPCR toxicity panels, error-corrected DNA sequencing for mutagenicity, and multi-omics profiling, along with benchmark dose modeling software, bioinformatics, and testing delivered by contract research organizations (CROs). Conventional in vivo studies without omics analysis, non-omics in vitro assays, standalone organoid and organ-on-chip products, clinical pharmacogenomic testing, and general genomics research are excluded.
According to the Food and Drug Administration (FDA) in the U.S., about 90% of drugs that clear animal studies are never approved because of safety or efficacy problems in humans, which is why drug developers want earlier and more predictive molecular data. In September 2026, the FDA issued a direct final rule that swaps the wording "animal tests" for "nonclinical tests" across its regulations and listed 25 cases where NAM data already feature in agency review documents. The European Commission's June 2026 roadmap toward phasing out animal testing for chemical safety covers 15 regulatory domains and notes that over 15 million animals went into EU regulatory testing between 2015 and 2023, close to 40% of them for chemical safety.
Few toxicogenomic methods have yet been validated or accepted as full substitutes for traditional studies, so some companies hesitate to fund data that a regulator may not accept, and meeting the FDA's evaluation criteria on context of use and human relevance takes time. Weaker biotech funding and pharmaceutical cost cutting have also softened demand for preclinical safety services at CROs. Linking gene expression shifts to true adverse outcomes remains hard, since some changes are adaptive rather than harmful, and large omics datasets call for specialist bioinformatics, while differences in study design and analysis pipelines still limit reproducibility despite the OECD omics reporting framework.
Pairing toxicogenomic readouts with human cell models, organoids, and organ-on-chip systems is a significant opportunity, as it supplies the human-relevant evidence regulators now ask for. AI models trained on large gene expression datasets can predict toxicity and support read-across, and the FDA's qualification of an AI tool for in silico models points to growing acceptance of computational methods. Error-corrected sequencing offers a richer alternative to transgenic rodent mutation assays, and the EU cosmetics testing ban and the Commission roadmap for pesticides, biocides, and industrial chemicals open demand beyond pharma. Key trends include the shift to high-throughput targeted transcriptomics, the integration of toxicogenomics into regulatory NAM frameworks, and the rise of multi-omics and single-cell toxicology.
By offering, the toxicogenomics market is segmented into reagents & kits, instruments, software & databases, and services. Reagents & kits are expected to hold the largest share in 2026, because library preparation kits, targeted assays, and sample preparation kits are consumed in every study, high-throughput projects keep raising sample counts, and pharmaceutical companies, CROs, and government laboratories all use sequencing and qPCR reagents. Software & databases are set to grow at the highest CAGR, as users need bioinformatics, benchmark dose modeling, and interpretation tools for large datasets, curated reference databases are gaining value for toxicity prediction and read-across, and AI is being applied to toxicogenomic data. Services are also expected to grow strongly as more studies move to CROs.
By technology, the toxicogenomics market is segmented into whole-transcriptome RNA sequencing, targeted transcriptomics, microarrays, quantitative PCR, error-corrected DNA sequencing, and other technologies such as epigenomic, proteomic, and metabolomic profiling. Whole-transcriptome RNA sequencing is expected to lead in 2026, as it gives complete and unbiased gene expression data, it is well established in pharmaceutical safety and mechanistic toxicology, and falling costs have led many laboratories to move away from microarrays. Targeted transcriptomics is projected to record the highest CAGR, owing to its low cost per sample, its high throughput without RNA extraction, and its use in government screening programs and in deriving points of departure for data-poor chemicals. Error-corrected DNA sequencing is also set for strong growth in mutagenicity testing.
By test system, the toxicogenomics market is segmented into in vitro models and in vivo models. In vivo models are expected to hold the largest share in 2026, as rodent and other animal studies remain part of regulatory toxicology, tissues from these studies are profiled for mechanisms and early markers, and most reference datasets are built on animal data. In vitro models are set to grow at the highest CAGR, as U.S. and European regulators push to cut animal use, human-relevant three-dimensional models and organ-on-chip systems are maturing, and cell-based formats suit high-throughput screening. Among in vitro formats, three-dimensional models, organoids, and organ-on-chip systems are gaining attention because they mimic human tissue responses more closely than two-dimensional cell cultures.
By application, the toxicogenomics market is segmented into drug discovery & development, chemical & agrochemical safety assessment, cosmetics & personal care safety assessment, food safety & environmental toxicology, and other applications. Drug discovery & development is expected to lead in 2026, reflecting how expensive safety failures are late in development, the reliance of drug makers on gene expression data to pick safer candidates and explain toxicity, and the FDA's push for NAMs in preclinical work. Chemical & agrochemical safety assessment is projected to register the highest CAGR, as many chemicals in commerce lack toxicity data, transcriptomic points of departure are entering risk assessment, and the Commission roadmap covers industrial chemicals, pesticides, and biocides. Within drug development, the report also tracks hepatotoxicity, nephrotoxicity, cardiotoxicity, and genotoxicity & carcinogenicity studies.
By end user, the toxicogenomics market is segmented into pharmaceutical & biotechnology companies, contract research organizations, chemical, agrochemical & cosmetics companies, and academic, government & regulatory research institutes. Pharmaceutical & biotechnology companies are expected to hold the largest share in 2026, given their heavy use of toxicogenomics in discovery and preclinical safety, large research budgets, and internal spending on sequencing platforms, data analysis, and human-based test models. Contract research organizations are expected to grow at the highest CAGR, supported by more outsourcing of safety studies, new NAM-based service lines, and demand from smaller biotech, chemical, and cosmetics firms that lack in-house expertise. Government and academic institutes continue to shape methods through programs such as Tox21 and EPA transcriptomics research.
North America is expected to be the largest regional toxicogenomics market in 2026, supported by its dense base of drug research, the FDA roadmap and NIH partnership, the FDA's 2026 rule on nonclinical methods, and Tox21 and EPA transcriptomic work. The region is also home to most of the leading suppliers and CROs, including Illumina, Thermo Fisher Scientific, Charles River Laboratories, and Labcorp. Europe holds a significant share, backed by the Commission roadmap, the EU cosmetics testing ban, large chemical and agrochemical industries, and NAM research programs, with QIAGEN and Eurofins Scientific active there.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, as pharmaceutical research and CRO capacity expand in China, India, and South Korea, Japan builds on its long experience through the Japanese Toxicogenomics Project, chemical and cosmetics industries grow, and regulators in China, South Korea, and other countries adopt alternative testing methods. Latin America and the Middle East & Africa hold smaller shares, with research capacity and alternative testing initiatives in Brazil and life science investment in the Gulf countries expected to support demand.
The toxicogenomics market is moderately fragmented, with life science tool suppliers, targeted transcriptomic platform and software developers, and CROs active across offerings and applications. Companies compete on profiling throughput and cost, data quality, access to validated toxicity signatures and reference databases, interpretation capability, human-relevant test systems, and regulatory experience. Leading players are launching targeted transcriptomic assays, combining toxicogenomics with organ-on-chip and other human cell models, building curated databases and AI tools, and adding NAM-based services, encouraged by the FDA's April 2026 progress report, the Commission roadmap, and the FDA's September 2026 rule.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), BioSpyder Technologies, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Laboratory Corporation of America Holdings (Labcorp) (U.S.), Inotiv, Inc. (U.S.), and Eurofins Scientific SE (Luxembourg).
The market includes the products and services used to measure how drugs, chemicals, and environmental agents alter gene expression and related molecular processes, so that hazards can be found, toxic mechanisms explained, and safety decisions supported. Covered methods include whole-transcriptome RNA sequencing, targeted and high-throughput transcriptomics, microarrays, qPCR toxicity panels, error-corrected DNA sequencing for mutagenicity, and multi-omics profiling, along with benchmark dose modeling software, bioinformatics, and testing delivered by contract research organizations (CROs). Conventional in vivo studies without omics analysis, non-omics in vitro assays, standalone organoid and organ-on-chip products, clinical pharmacogenomic testing, and general genomics research are excluded.
According to the Food and Drug Administration (FDA) in the U.S., about 90% of drugs that clear animal studies are never approved because of safety or efficacy problems in humans, which is why drug developers want earlier and more predictive molecular data. In September 2026, the FDA issued a direct final rule that swaps the wording "animal tests" for "nonclinical tests" across its regulations and listed 25 cases where NAM data already feature in agency review documents. The European Commission's June 2026 roadmap toward phasing out animal testing for chemical safety covers 15 regulatory domains and notes that over 15 million animals went into EU regulatory testing between 2015 and 2023, close to 40% of them for chemical safety.
Market Dynamics
Regulatory support for NAMs is driving the toxicogenomics market, led by the FDA's progress on its 2025 roadmap to reduce animal use in preclinical safety work, its March 2026 draft guidance favoring a weight-of-evidence approach based on in vitro and computational data, and its tie-up with the National Institutes of Health (NIH) to put human-relevant science at the center of drug review. High safety-related attrition adds a commercial reason to adopt these tools, as early signals of liver, kidney, and cardiac toxicity let companies rank compounds and drop risky candidates before costly animal and clinical work. Cheaper sequencing and lysate-based targeted assays now make concentration-response studies and large chemical screens affordable, and agencies in the U.S., Canada, and Europe are testing transcriptomic points of departure as a quicker way to assess data-poor chemicals.Few toxicogenomic methods have yet been validated or accepted as full substitutes for traditional studies, so some companies hesitate to fund data that a regulator may not accept, and meeting the FDA's evaluation criteria on context of use and human relevance takes time. Weaker biotech funding and pharmaceutical cost cutting have also softened demand for preclinical safety services at CROs. Linking gene expression shifts to true adverse outcomes remains hard, since some changes are adaptive rather than harmful, and large omics datasets call for specialist bioinformatics, while differences in study design and analysis pipelines still limit reproducibility despite the OECD omics reporting framework.
Pairing toxicogenomic readouts with human cell models, organoids, and organ-on-chip systems is a significant opportunity, as it supplies the human-relevant evidence regulators now ask for. AI models trained on large gene expression datasets can predict toxicity and support read-across, and the FDA's qualification of an AI tool for in silico models points to growing acceptance of computational methods. Error-corrected sequencing offers a richer alternative to transgenic rodent mutation assays, and the EU cosmetics testing ban and the Commission roadmap for pesticides, biocides, and industrial chemicals open demand beyond pharma. Key trends include the shift to high-throughput targeted transcriptomics, the integration of toxicogenomics into regulatory NAM frameworks, and the rise of multi-omics and single-cell toxicology.
Segment Analysis
The report analyzes the market by offering, technology, test system, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, service expansion, and investment.By offering, the toxicogenomics market is segmented into reagents & kits, instruments, software & databases, and services. Reagents & kits are expected to hold the largest share in 2026, because library preparation kits, targeted assays, and sample preparation kits are consumed in every study, high-throughput projects keep raising sample counts, and pharmaceutical companies, CROs, and government laboratories all use sequencing and qPCR reagents. Software & databases are set to grow at the highest CAGR, as users need bioinformatics, benchmark dose modeling, and interpretation tools for large datasets, curated reference databases are gaining value for toxicity prediction and read-across, and AI is being applied to toxicogenomic data. Services are also expected to grow strongly as more studies move to CROs.
By technology, the toxicogenomics market is segmented into whole-transcriptome RNA sequencing, targeted transcriptomics, microarrays, quantitative PCR, error-corrected DNA sequencing, and other technologies such as epigenomic, proteomic, and metabolomic profiling. Whole-transcriptome RNA sequencing is expected to lead in 2026, as it gives complete and unbiased gene expression data, it is well established in pharmaceutical safety and mechanistic toxicology, and falling costs have led many laboratories to move away from microarrays. Targeted transcriptomics is projected to record the highest CAGR, owing to its low cost per sample, its high throughput without RNA extraction, and its use in government screening programs and in deriving points of departure for data-poor chemicals. Error-corrected DNA sequencing is also set for strong growth in mutagenicity testing.
By test system, the toxicogenomics market is segmented into in vitro models and in vivo models. In vivo models are expected to hold the largest share in 2026, as rodent and other animal studies remain part of regulatory toxicology, tissues from these studies are profiled for mechanisms and early markers, and most reference datasets are built on animal data. In vitro models are set to grow at the highest CAGR, as U.S. and European regulators push to cut animal use, human-relevant three-dimensional models and organ-on-chip systems are maturing, and cell-based formats suit high-throughput screening. Among in vitro formats, three-dimensional models, organoids, and organ-on-chip systems are gaining attention because they mimic human tissue responses more closely than two-dimensional cell cultures.
By application, the toxicogenomics market is segmented into drug discovery & development, chemical & agrochemical safety assessment, cosmetics & personal care safety assessment, food safety & environmental toxicology, and other applications. Drug discovery & development is expected to lead in 2026, reflecting how expensive safety failures are late in development, the reliance of drug makers on gene expression data to pick safer candidates and explain toxicity, and the FDA's push for NAMs in preclinical work. Chemical & agrochemical safety assessment is projected to register the highest CAGR, as many chemicals in commerce lack toxicity data, transcriptomic points of departure are entering risk assessment, and the Commission roadmap covers industrial chemicals, pesticides, and biocides. Within drug development, the report also tracks hepatotoxicity, nephrotoxicity, cardiotoxicity, and genotoxicity & carcinogenicity studies.
By end user, the toxicogenomics market is segmented into pharmaceutical & biotechnology companies, contract research organizations, chemical, agrochemical & cosmetics companies, and academic, government & regulatory research institutes. Pharmaceutical & biotechnology companies are expected to hold the largest share in 2026, given their heavy use of toxicogenomics in discovery and preclinical safety, large research budgets, and internal spending on sequencing platforms, data analysis, and human-based test models. Contract research organizations are expected to grow at the highest CAGR, supported by more outsourcing of safety studies, new NAM-based service lines, and demand from smaller biotech, chemical, and cosmetics firms that lack in-house expertise. Government and academic institutes continue to shape methods through programs such as Tox21 and EPA transcriptomics research.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 17 countries and four rest-of-region groups. The regional analysis considers pharmaceutical and chemical research activity, policy on animal testing and NAMs, government programs, CRO capacity, and the presence of technology providers.North America is expected to be the largest regional toxicogenomics market in 2026, supported by its dense base of drug research, the FDA roadmap and NIH partnership, the FDA's 2026 rule on nonclinical methods, and Tox21 and EPA transcriptomic work. The region is also home to most of the leading suppliers and CROs, including Illumina, Thermo Fisher Scientific, Charles River Laboratories, and Labcorp. Europe holds a significant share, backed by the Commission roadmap, the EU cosmetics testing ban, large chemical and agrochemical industries, and NAM research programs, with QIAGEN and Eurofins Scientific active there.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, as pharmaceutical research and CRO capacity expand in China, India, and South Korea, Japan builds on its long experience through the Japanese Toxicogenomics Project, chemical and cosmetics industries grow, and regulators in China, South Korea, and other countries adopt alternative testing methods. Latin America and the Middle East & Africa hold smaller shares, with research capacity and alternative testing initiatives in Brazil and life science investment in the Gulf countries expected to support demand.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis, together with company profiles that include business overviews, financial performance, toxicogenomics and product/service portfolios, strategic developments, and SWOT analyses.The toxicogenomics market is moderately fragmented, with life science tool suppliers, targeted transcriptomic platform and software developers, and CROs active across offerings and applications. Companies compete on profiling throughput and cost, data quality, access to validated toxicity signatures and reference databases, interpretation capability, human-relevant test systems, and regulatory experience. Leading players are launching targeted transcriptomic assays, combining toxicogenomics with organ-on-chip and other human cell models, building curated databases and AI tools, and adding NAM-based services, encouraged by the FDA's April 2026 progress report, the Commission roadmap, and the FDA's September 2026 rule.
Key companies profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), BioSpyder Technologies, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Laboratory Corporation of America Holdings (Labcorp) (U.S.), Inotiv, Inc. (U.S.), and Eurofins Scientific SE (Luxembourg).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global toxicogenomics market.
- Explains how FDA and European Commission initiatives to reduce animal testing are creating demand for toxicogenomic data.
- Assesses the impact of limited method validation, data interpretation challenges, and preclinical spending pressure on adoption.
- Identifies high-growth opportunities across offering, technology, test system, application, end user, and region.
- Tracks targeted transcriptomics, error-corrected sequencing, organ-on-chip integration, and AI-based toxicity prediction.
- Benchmarks leading technology providers and CROs by portfolio, throughput, databases, and regulatory experience.
- Supports product planning, partnering, and market entry decisions for suppliers, CROs, chemical and drug companies, and investors.
Key Questions Answered
- How big is the global toxicogenomics market today, and how will it grow through 2036?
- How are the FDA roadmap, the FDA nonclinical methods rule, and the European Commission roadmap changing safety testing?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are transcriptomic points of departure being used in chemical risk assessment?
- Which offering, technology, test system, application, and end user segments will grow the fastest?
- How will targeted transcriptomics and in vitro models change toxicogenomic study design?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and how do they compete?
- What strategies are suppliers and CROs adopting to strengthen their NAM portfolios?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Toxicogenomics Market, by Offering
6. Toxicogenomics Market, by Technology
7. Toxicogenomics Market, by Test System
8. Toxicogenomics Market, by Application
9. Toxicogenomics Market, by End User
10. Toxicogenomics Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- BioSpyder Technologies, Inc.
- Charles River Laboratories International, Inc.
- Laboratory Corporation of America Holdings
- Inotiv, Inc.
- Eurofins Scientific SE
